Soliton Interactions in Perturbed Nonlinear Schroedinger Equations

We use multiscale perturbation theory in conjunction with the inverse scattering transform to study the interaction of a number of solitons of the cubic nonlinear Schroedinger equation under the influence of a small correction to the nonlinear potential. We assume that the solitons are all moving with the same velocity at the initial instant; this maximizes the effect each soliton has on the others as a consequence of the perturbation. Over the long time scales that we consider, the amplitudes of the solitons remain fixed, while their center of mass coordinates obey Newton's equations with a force law for which we present an integral formula. For the interaction of two solitons with a quintic perturbation term we present more details since symmetries -- one related to the form of the perturbation and one related to the small number of particles involved -- allow the problem to be reduced to a one-dimensional one with a single parameter, an effective mass. The main results include calculations of the binding energy and oscillation frequency of nearby solitons in the stable case when the perturbation is an attractive correction to the potential and of the asymptotic "ejection" velocity in the unstable case. Numerical experiments illustrate the accuracy of the perturbative calculations and indicate their range of validity.Comment: 28 pages, 7 figures, Submitted to Phys Rev E Revised: 21 pages, 6 figures, To appear in Phys Rev E (many displayed equations moved inline to shorten manuscript

Stability of stationary states in the cubic nonlinear Schroedinger equation: applications to the Bose-Einstein condensate

The stability properties and perturbation-induced dynamics of the full set of stationary states of the nonlinear Schroedinger equation are investigated numerically in two physical contexts: periodic solutions on a ring and confinement by a harmonic potential. Our comprehensive studies emphasize physical interpretations useful to experimentalists. Perturbation by stochastic white noise, phase engineering, and higher order nonlinearity are considered. We treat both attractive and repulsive nonlinearity and illustrate the soliton-train nature of the stationary states.Comment: 9 pages, 11 figure

Deteksi Antibodi terhadap Mycoplasma gallisepticum pada Serum Ayam dengan Pengujian Serologi Rapid Serum Agglutination (RSA), Kit ELISA Komersil dan inhouseELISA

Mycoplasma gallisepticum (MG) adalah bakteri penyebab penyakit pernapasan kronis pada ayam yang sering disebut sebagai chronic respiratory disease (CRD) dan infectious sinusitis pada kalkun. Kerugian akibat infeksi MG pada industri perunggasan di dunia mencapai lebih dari US $ 780 juta setiap tahun. Deteksi dini dan monitoring secara berkelanjutan sangat dibutuhkan dari hulu yakni hatchery sampai ke hilir di peternakan komersil. Di Indonesia kasus CRD maupun CRD kompleks sampai saat ini masih menjadi permasalahan di peternakan-peternakan ayam. Keberadaan MG dapat dideteksi dengan cara isolasi organisme atau deteksi DNA dari jaringan yang terinfeksi atau sampel swab atau dengan menggunakan pengujian serologi untuk diagnosis penyakit ini. Jenis pengujian serologi yang sudah umum dilakukan adalah dengan Rapid Serum Agglutination (RSA), Enzyme-Linked Immunosorbent Assay (ELISA) dan Haemagglutination Inhibition (HI). Penelitian ini bertujuan untuk mengetahui status antibodi ayam dari beragam kondisi di lapangan dengan uji RSA, ELISA komersil dan inhouseELISA (iELISA). Pengujian serologi dengan menggunakan 3 jenis pengujian memberikan hasil yang berbeda dalam mendeteksi antibodi terhadap MG pada sampel serum ayam dengan status yang bervariasi. Kit ELISA komersil lebih sensitif dalam mendeteksi antibodi terhadap MG, sehingga pengujian ini memberikan hasil positif paling banyak

Host markers in Quantiferon supernatants differentiate active TB from latent TB infection: preliminary report

<p>Abstract</p> <p>Background</p> <p>Interferon gamma release assays, including the QuantiFERON^®TB Gold In Tube (QFT) have been shown to be accurate in diagnosing <it>Mycobacterium tuberculosis </it>infection. These assays however, do not discriminate between latent TB infection (LTBI) and active TB disease.</p> <p>Methods</p> <p>We recruited twenty-three pulmonary TB patients and 34 household contacts from Cape Town, South Africa and performed the QFT test. To investigate the ability of new host markers to differentiate between LTBI and active TB, levels of 29 biomarkers in QFT supernatants were evaluated using a Luminex multiplex cytokine assay.</p> <p>Results</p> <p>Eight out of 29 biomarkers distinguished active TB from LTBI in a pilot study. Baseline levels of epidermal growth factor (EGF) soluble CD40 ligand (sCD40L), antigen stimulated levels of EGF, and the background corrected antigen stimulated levels of EGF and macrophage inflammatory protein (MIP)-1β were the most informative single markers for differentiation between TB disease and LTBI, with AUCs of 0.88, 0.84, 0.87, 0.90 and 0.79 respectively. The combination of EGF and MIP-1β predicted 96% of active TB cases and 92% of LTBIs. Combinations between EGF, sCD40L, VEGF, TGF-α and IL-1α also showed potential to differentiate between TB infection states. EGF, VEGF, TGF-α and sCD40L levels were higher in TB patients.</p> <p>Conclusion</p> <p>These preliminary data suggest that active TB may be accurately differentiated from LTBI utilizing adaptations of the commercial QFT test that includes measurement of EGF, sCD40L, MIP-1β, VEGF, TGF-α or IL-1α in supernatants from QFT assays. This approach holds promise for development as a rapid diagnostic test for active TB.</p

Potential of novel Mycobacterium tuberculosis infection phase-dependent antigens in the diagnosis of TB disease in a high burden setting

<p>Abstract</p> <p>Background</p> <p>Confirming tuberculosis (TB) disease in suspects in resource limited settings is challenging and calls for the development of more suitable diagnostic tools. Different <it>Mycobacterium tuberculosis (M.tb) </it>infection phase-dependent antigens may be differentially recognized in infected and diseased individuals and therefore useful as diagnostic tools for differentiating between <it>M.tb </it>infection states. In this study, we assessed the diagnostic potential of 118 different <it>M.tb </it>infection phase-dependent antigens in TB patients and household contacts (HHCs) in a high-burden setting.</p> <p>Methods</p> <p>Antigens were evaluated using the 7-day whole blood culture technique in 23 pulmonary TB patients and in 19 to 21 HHCs (total n = 101), who were recruited from a high-TB incidence community in Cape Town, South Africa. Interferon-gamma (IFN-γ) levels in culture supernatants were determined by ELISA.</p> <p>Results</p> <p>Eight classical TB vaccine candidate antigens, 51 DosR regulon encoded antigens, 23 TB reactivation antigens, 5 TB resuscitation promoting factors (rpfs), 6 starvation and 24 other stress response-associated TB antigens were evaluated in the study. The most promising antigens for ascertaining active TB were the rpfs (Rv0867c, Rv2389c, Rv2450c, Rv1009 and Rv1884c), with Areas under the receiver operating characteristics curves (AUCs) between 0.72 and 0.80. A combination of <it>M.tb </it>specific ESAT-6/CFP-10 fusion protein, Rv2624c and Rv0867c accurately predicted 73% of the TB patients and 80% of the non-TB cases after cross validation.</p> <p>Conclusions</p> <p>IFN-γ responses to TB rpfs show promise as TB diagnostic candidates and should be evaluated further for discrimination between <it>M.tb </it>infection states.</p

CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS

Objective: This study evaluated the efficacy and safety of ATL1102, an antisense oligonucleotide that selectively targets the RNA for human CD49d, the a subunit of very late antigen 4, in patients with relapsing-remitting multiple sclerosis (RRMS). Methods: In a multicenter, double-blind, placebo-controlled randomized phase II trial, 77 patients with RRMS were treated with 200 mg of ATL1102 subcutaneously injected 3 times in the first week and twice weekly for 7 weeks or placebo and monitored for a further 8 weeks. MRI scans were taken at baseline and weeks 4, 8, 12, and 16. The primary endpoint was the cumulative number of new active lesions (either new gadolinium-enhancing T1 lesions or nonenhancing new or enlarging T2 lesions) at weeks 4, 8, and 12. Results: A total of 72 patients completed the study and 74 intention-to-treat patients were assessed. ATL1102 significantly reduced the cumulative number of new active lesions by 54.4% compared to placebo (mean 3.0 [SD 6.12] vs 6.2 [9.89], p = 0.01). The cumulative number of new gadolinium-enhancing T1 lesions was reduced by 67.9% compared to placebo (p = 0.002). Treatment-emergent adverse events included mild to moderate injection site erythema and decrease in platelet counts that returned to within the normal range after dosing. Conclusions: In patients with RRMS, ATL1102 significantly reduced disease activity after 8 weeks of treatment and was generally well-tolerated. This trial provides evidence for the first time that antisense oligonucleotides may be used as a therapeutic approach in neuroimmunologic disorders. Classification: This study provides Class I evidence that for patients with RRMS, the antisense oligonucleotide ATL1102 reduces the number of new active head MRI lesions

Restriction fragment length polymorphism analysis of genes of virulent strain isolate of Toxoplasma gondii using enzyme DdeI

Background and Aim: Toxoplasma gondii is a unicellular coccidian parasite distributed globally and is an important zoonotic pathogen. Approximately 30% of the human population worldwide is chronically infected with T. gondii. The pathogenicity of this species depends on the type originating from the clonal population. Techniques for more accurately determining the type of T. gondii have recently been developed using genetic markers. Specifically, T. gondii has been typed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). This study aimed to identify sets of PCR-RFLP markers that have high power to discriminate genotyping of T. gondii and are easy to use and are easy to use. The objective of this study was to characterize virulent strain isolates of T. gondii by PCR-RFLP using 10 markers with DdeI. Materials and Methods: T. gondii tachyzoites (RH virulent strain) were derived from culture cells at the Indonesian Research Center for Veterinary Sciences. Genotyping was performed on T. gondii DNA extracted from cell cultured tachyzoites using 10 genetic markers of PCR-RFLP, namely, B1#1, B1#2, B1#3, SAG1#1, SAG1#2, P30, BAG1, ROP1, GRA1, and GRA7, with digestion using the restriction enzyme DdeI. Results: The 10 genes were amplified by PCR. Among them, three genetic markers, B1#3, ROP1, and GRA1, were genotyped by the PCR-RFLP using restriction enzyme DdeI. Overall, the findings showed that the specific RFLP profile of digestion of gene regions by DdeI could be used as a specific marker for the virulent biotype causative of toxoplasmosis. In addition, virulent strains of T. gondii can be easily detected by these markers. Conclusion: Three pairs of primers (B1#3, ROP1, and GRA1) with DdeI have proven useful for the diagnosis of acute toxoplasmosis (virulent strain biotype I). This proposed method is relatively simple, rapid, cheap, and can be performed in most laboratories, providing a practical approach for the routine analysis of T. gondii strains.</jats:p

EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.

BACKGROUND: Existing treatments for postherpetic neuralgia, and for neuropathic pain in general, are limited by modest efficacy and unfavourable side-effects. The angiotensin II type 2 receptor (AT2R) is a new target for neuropathic pain. EMA401, a highly selective AT2R antagonist, is under development as a novel neuropathic pain therapeutic agent. We assessed the therapeutic potential of EMA401 in patients with postherpetic neuralgia. METHODS: In this multicentre, placebo-controlled, double-blind, randomised, phase 2 clinical trial, we enrolled patients (aged 22-89 years) with postherpetic neuralgia of at least 6 months' duration from 29 centres across six countries. We randomly allocated 183 participants to receive either oral EMA401 (100 mg twice daily) or placebo for 28 days. Randomisation was done according to a centralised randomisation schedule, blocked by study site, which was generated by an independent, unmasked statistician. Patients and staff at each site were masked to treatment assignment. We assessed the efficacy, safety, and pharmacokinetics of EMA401. The primary efficacy endpoint was change in mean pain intensity between baseline and the last week of dosing (days 22-28), measured on an 11-point numerical rating scale. The primary efficacy analysis was intention to treat. This trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12611000822987. FINDINGS: 92 patients were assigned to EMA401 and 91 were assigned to placebo. The patients given EMA401 reported significantly less pain compared with baseline values in the final week of treatment than did those given placebo (mean reductions in pain scores -2.29 [SD 1.75] vs -1.60 [1.66]; difference of adjusted least square means -0.69 [SE 0.25]; 95% CI -1.19 to -0.20; p=0.0066). No serious adverse events related to EMA401 occurred. Overall, 32 patients reported 56 treatment-emergent adverse events in the EMA401 group compared with 45 such events reported by 29 patients given placebo. INTERPRETATION: EMA401 (100 mg twice daily) provides superior relief of postherpetic neuralgia compared with placebo at the end of 28 days of treatment. EMA401 was well tolerated by patients. FUNDING: Spinifex Pharmaceuticals